




RealRate

PHARMACEUTICAL 2024

Biofrontera Inc
Rank 215 of 309

us.com the alternative.com
PERFECT FOR AMERICAN COMPANIES AND WEBSITES TARGETING THE AMERICAN MARKET



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biofrontera Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Biofrontera Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 74% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	23,075
Cost of Goods Sold	0
Intangible Assets	2,629
Liabilities, Current	18,088
Liabilities, Non-Current	841
Other Assets	2,094
Other Compr. Net Income	0
Other Expenses	17,710
Other Liabilities	4,210
Other Net Income	2,560
Other Revenues	34,071
Property and Equipment	134
Research and Development	77
Selling, General and Administrative Expense	38,975

Output Variable	Value in 1000 USD
Assets	27,932
Liabilities	23,139
Expenses	56,762
Revenues	34,071
Stockholders Equity	4,793
Net Income	-20,131
Comprehensive Net Income	-20,131
BaseVar	72,232
ECR before LimitedLiability	-38%
Economic Capital Ratio	139%